4D Molecular Therapeutics (FDMT) Depreciation and Depletion (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Depreciation and Depletion of $1.3 million for Q1 2026, little changed year-over-year from $1.3 million in Q1 2025, and little changed quarter-over-quarter from $1.3 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Depreciation and Depletion (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Depreciation and Depletion for 7 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation and Depletion changed 0.0% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $5.2 million (up 6.12% YoY), while the FY2025 annual figure was $5.2 million, up 8.33% from the prior year.
- Depreciation and Depletion steadied at $1.3 million in Q1 2026 per FDMT's latest filing, from $1.3 million in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $1.3 million in Q4 2023 and bottomed at $400000.0 in Q1 2022.
- Historically, Depreciation and Depletion has averaged $1.1 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2022 — Depreciation and Depletion surged 150.0% — and 2024, when it slipped 7.69%.
- 4D Molecular Therapeutics' Depreciation and Depletion stood at $1.0 million in 2022, then increased by 30.0% to $1.3 million in 2023, then slipped by 7.69% to $1.2 million in 2024, then climbed by 8.33% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
- Business Quant data shows FDMT's Depreciation and Depletion at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 38.91 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Mn |
| Jun 30, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |